Benzaghou joins Mammen-led Parabilis as CMO
Plus: Weinreich named head of R&D, CMO at Merck KGaA; updates from Maze, Pharming, Perspective and more
Fawzi Benzaghou is joining Parabilis Medicines Inc. as CMO. He arrives from Ipsen Group (Euronext:IPN; Pink:IPSEY), where he was SVP and global head of oncology. Formerly known as Fog Pharmaceuticals Inc. and led by Chairman, President and CEO Mathai Mammen, Parabilis is preparing to present clinical data for its β-catenin (CTNNB1) inhibitor at next month’s ESMO Congress 2025.
Merck KGaA (Xetra:MRK) has hired David Weinreich to be its global head of R&D and CMO, in its healthcare business. He arrives from a two-year stint as an operating partner at Foresite Labs and senior adviser to Foresite Capital; previously, he had held executive development roles at Regeneron Pharmaceuticals Inc. (NASDAQ:REGN), Bayer AG (Xetra:BAYN) and Amgen Inc. (NASDAQ:AMGN)...